Holen Sie sich die Stockscreener-App
14.15
3.40%
-0.4999
Schlusskurs vom Vortag:
$14.65
Offen:
$15.15
24-Stunden-Volumen:
2.31M
Relative Volume:
0.42
Marktkapitalisierung:
$4.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-127.69M
KGV:
-31.39
EPS:
-0.4508
Netto-Cashflow:
$-98.43M
1W Leistung:
-8.52%
1M Leistung:
+17.94%
6M Leistung:
+807.21%
1J Leistung:
+862.75%
1-Tages-Spanne:
$13.97
$15.56
1-Wochen-Bereich:
$13.97
$16.41
52-Wochen-Spanne:
$1.01
$16.41
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
14.15 | 4.54B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.30 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.47 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.27 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - Bitget
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 - Investing.com Nigeria
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau - Bitget
Global cancer drug rights: Erasca takes ERAS-0015 worldwide - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 52-Week HighTime to Buy? - MarketBeat
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - 24/7 Wall St.
Growth Recap: How interest rate cuts could boost Erasca Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - Naître et grandir
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - The Globe and Mail
Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com
Erasca’s chief medical officer Morris sells $300k in ERAS stock - Investing.com
Erasca (ERAS) Sees Target Price Raised By Clear Street To $20 | - GuruFocus
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Sahm
Tango Therapeutics rallies after oncology drug collaboration with Erasca - Mugglehead Investment Magazine
Clear Street raises Erasca stock price target on combination trial deal - Investing.com Australia
Erasca and Tango Therapeutics Partner to Study ERAS-007 and Vopimetostat Combination for MTAP-Deleted Cancers - geneonline.com
Assessing Tango Therapeutics (TNGX) Valuation After Earnings Update And New Erasca Trial Collaboration - simplywall.st
Tango rises after Q4 results, clinical pact with Erasca - Seeking Alpha
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat - Bitget
Biopharmaceutical company Erasca, Inc. (NASDAQ: ERAS) and Tango Therapeutics Inc. (NASDAQ: TNGX) announced a clinical collaboration to jointly conduct clinical evaluation of the combination therapy of ERAS-0015 and vopimetostat. - Bitget
Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy - marketscreener.com
Erasca and Tango Therapeutics enter into clinical collaboration to evaluate combination of ERAS-0015 and vopimetostat - marketscreener.com
Erasca, Tango test dual-drug attack on tough pancreatic, lung cancers - Stock Titan
Erasca Inc stock hits 52-week high at $14.63 By Investing.com - Investing.com Canada
Erasca stock reaches 52-week high at 12.48 USD - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Erasca, Inc. (ERAS): A Bull Case Theory - Insider Monkey
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca stock hits 52-week high at $13.30 By Investing.com - Investing.com India
Assessing Erasca (ERAS) Valuation After New Pan KRAS Patent Win Through 2043 - simplywall.st
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors - marketscreener.com
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - Bitget
New Erasca patent protects ERAS-4001 for RAS-driven cancers to 2043 - Stock Titan
Will Erasca Inc. outperform small cap indexes2025 Pullback Review & AI Optimized Trading Strategy Guides - mfd.ru
Setup Watch: How does Erasca Inc perform in inflationary periods2025 Major Catalysts & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):